Biotech Values

[DewDiligence]

(ENTA)—JNJ formally abandons RSV program:

https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm

On March 21, 2019, Johnson & Johnson…determined that it will record an intangible asset impairment charge related to an in-process research and development asset, AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV), with a carrying value of approximately $900 million acquired in the acquisition of Alios Biopharma Inc. in 2014.

Additional information became available which led the Company to the decision to abandon the development of AL-8176.

Bullish for ENTA, of course. (h/t @bio_clouseau.)